NOTICE:

In 2010, Optherion completed two separate business transactions, one related to its diagnostics business and one related to its therapeutics business.

With respect to its diagnostics business, in February, 2010, Optherion completed an exclusive worldwide licensing agreement with Sequenom, Inc.. Under the agreement, Sequenom’s CAP accredited and CLIA-certified laboratory, Sequenom Center for Molecular Medicine (Sequenom CMM), obtained the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD). Please see News Room at Optherion.com for Sequenom’s press release.

With respect to its therapeutics business, also in 2010, Optherion completed a business transaction with another company. Both the company name and the transaction economics are confidential.

As a result of these two transactions, Optherion, itself, is no longer actively developing any diagnostics or therapeutics. Given this, the Optherion.com website has not been updated since year-end, 2010 albeit the nature of Optherion’s diagnostic and therapeutic endeavors are accurately represented in the website for the time period prior to the transactions.

Kindest regards,

Colin J. Foster
President & CEO
Optherion, Inc.

Optherion Announces Presentation at ARVO 2009 Annual Meeting

A Clinical Study to Identify a Population with Blood-Based Biomarkers for Age-Related Macular Degeneration (AMD)

NEW HAVEN, CT (April [29], 2009)—Optherion, Inc., a company developing novel molecular diagnostics and treatments for dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, announced today that it will be reporting data from its diagnostics development program at The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Ft Lauderdale, FL, from May 3-7, 2009.

The title of the poster presentation is “A Clinical Study to Identify a Population with Blood-Based Biomarkers for Age-Related Macular Degeneration (AMD)”
Authors: D. Weaver, G. Ligon, K. Hade, L. Perlee, D. Grant, M. Patel, M. Modi.
Sunday, May 03, 2009, 11:15 AM - 1:00 PM
Poster #744/D798   Location Hall B/C

Colin J. Foster, Optherion’s President and CEO, said: “We are pleased with the results from this prospective clinical study in subjects across a broad age range that validate earlier reports describing the population distribution of genetic markers of AMD.   This study assists us in completing the development of a genetic test that will inform prognosis and risk of AMD”.

Request a copy of the ARVO Poster